Unicycive Therapeutics (UNCY) Return on Capital Employed (2021 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Return on Capital Employed came in at 98.95% in Q1 2026, up 13638.0% YoY from N/an in Q1 2025, and down 3.69% on a QoQ basis from 95.42% in Q4 2025.
Unicycive Therapeutics (UNCY) Return on Capital Employed (2021 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 6 years of Return on Capital Employed data on file, last reported at 98.95% in Q1 2026.
- Quarterly Return on Capital Employed rose 13638.0% year-over-year to 98.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.95% (up 13638.0% YoY) and the FY2025 annual result came in at 137.52%, down 283530.0% from the prior year.
- Return on Capital Employed slipped to 98.95% in Q1 2026, from 95.42% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 2895.47% in Q4 2023 to a low of 857.52% in Q1 2024.
- A 5-year average of 70.64% and a median of 127.82% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed soared 345723 bps — and 2024, when it slumped 318742 bps.
- Tracing UNCY's Return on Capital Employed over 5 years: stood at 561.76% in 2022, then surged by 615 bps to 2895.47% in 2023, then plunged by 110 bps to 291.95% in 2024, then soared by 67 bps to 95.42% in 2025, then retreated by 4 bps to 98.95% in 2026.
- The last three Return on Capital Employed figures came in at 98.95% (Q1 2026), 95.42% (Q4 2025), and 116.13% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | -66.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -66.94% |
| Mar 31, 2026 | -98.95% |
| Dec 31, 2025 | -95.42% |
| Sep 30, 2025 | -116.13% |
| Jun 30, 2025 | -197.75% |
| Mar 31, 2025 | -235.33% |
| Dec 31, 2024 | -291.95% |
| Sep 30, 2024 | -93.55% |
| Jun 30, 2024 | -81.38% |
| Mar 31, 2024 | -857.52% |
| Dec 31, 2023 | 2,895.47% |
| Sep 30, 2023 | -346.74% |
| Jun 30, 2023 | -201.62% |
| Mar 31, 2023 | 1,949.69% |
| Dec 31, 2022 | -561.76% |
| Sep 30, 2022 | -259.08% |
| Jun 30, 2022 | -127.82% |
| Mar 31, 2022 | -79.35% |
| Dec 31, 2021 | -52.32% |
| Sep 30, 2021 | -72.60% |